The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

International Journal of COPD

Volumn 12, Issue , 2017, Pages 1325-1337

  Anzueto, Antonio R ^a,b   Vogelmeier, Claus F ^c   Kostikas, Konstantinos ^d   Mezzi, Karen ^d   Fucile, Sebastian ^d   Bader, Giovanni ^d   Shen, Steven ^d   Banerji, Donald ^d   Fogel, Robert ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

COPD; Deterioration; IND GLY

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; GLYCOPYRRONIUM; INDACATEROL-GLYCOPYRRONIUM COMBINATION; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE; TIOTROPIUM BROMIDE;

AGED; BIOASSAY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG EFFECTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; KAPLAN MEIER METHOD; LUNG; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; ENDPOINT DETERMINATION; FEMALE; FLUTICASONE-SALMETEROL DRUG COMBINATION; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; GLYCOPYRROLATE; HUMANS; INDANS; KAPLAN-MEIER ESTIMATE; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 85019129975     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S133307     Document Type: Article

References (23)

1. goldcopd.org [homepage on the Internet]. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); as current in 2017. Available from: http://goldcopd.org. Accessed March 26, 2017.
2. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008; 178(4):332–338.
3. Spencer S, Calverley PM, Sherwood Burge P, Jones PW; ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(1):122–128.
4. Wilke S, Jones PW, Mullerova H, et al. One-year change in health status and subsequent outcomes in COPD. Thorax. 2015;70(5):420–425.
5. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852.
6. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19(116):113–118.
7. Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11: 1413–1424.
8. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494.
9. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209.
10. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234.
11. Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015–1026.
12. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMI-NATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.
13. goldcopd.org [homepage on the Internet]. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; as current in 2008. Available from: http://goldcopd.org. Accessed March 26, 2017.
14. goldcopd.org [homepage on the Internet]. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); as current in 2009. Available from: http://goldcopd.org. Accessed March 26, 2017.
15. goldcopd.org [homepage on the Internet]. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); as current in 2010. Available from: http://goldcopd.org. Accessed March 26, 2017.
16. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012.
17. Briggs A, Spencer M, Wang H, Mannino D, Sin DD. Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med. 2008; 168(1):71–79.
18. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009; 180(12):1189–1195.
19. Celli BR, Decramer M, Liu D, Metzdorf N, Asijee GM, Tashkin DP. Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial. Respir Res. 2016;17(1):48.
20. Naya I, Tombs T, Mullerova H, Compton C, Jones P. Long-term outcome following first clinically important deterioration in COPD. Eur Respir J. 2016;48:304.
21. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11):993–1004.
22. Tsutsui H, Momomura S, Saito Y, et al. Efficacy and safety of sacu-bitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. J Cardiol. Epub 2016 Dec 23.
23. Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2017; 33(12):2188–2199.